

**“Best of the AAHKS 2015 Fall Meeting”**

**AAHKS 2016 Spring Meeting**

Gregory G Polkowski, MD, MSc

Assistant Professor of Orthopaedic Surgery

Vanderbilt Orthopaedic Institute

2015 AAHKS Annual Meeting Program Chair

# Disclosures

**Gregory G Polkowski, II MD**, No financial relationships with commercial interests to disclose

**William P Barrett, MD**, DePuy, A Johnson & Johnson Company

**Stephen Thomas Duncan, MD**, Biomet; Mitek; Morph; Smith & Nephew

**William L Griffin, MD**, DePuy, A Johnson & Johnson Company; Zimmer

**Brian S Parsley, MD**, Conformis; DePuy, A Johnson & Johnson Company; Nimbic Systems



# “Best of Symposium”

Gregory G Polkowski, MD, MSc

Moderator

Brian Parsley, MD

William Griffin, MD


William Barret, MD

Stephen Duncan, MD



# 2015 AAHKS Annual Meeting

- Year for the record books
- 25<sup>th</sup> Anniversary
- Most abstracts submitted
  - ~1300
  - 59 papers (4.5% acceptance rate)
  - 200 posters (15%)
- Record attendance
  - ~2400 total
    - 1600 clinical
    - 400 more than 2014



# Pre-Meeting Courses

- 7<sup>th</sup> Annual Residents Course
  - Keith Berend and Matt Austin
- 5<sup>th</sup> Annual Team Member Course
  - David Dalury and Chris Peters
- 1<sup>st</sup> Annual “The Business of Total Joint Replacement, Surviving and Thriving”
  - Lawry Barnes and Mark Froimson
- Industry Symposia
  - 15 Total



# Recognition

- Guest Nations
  - Chilean Hip Society
  - Japanese Society for Replacement Arthroplasty
- AAHKS Humanitarian Award Recipient
  - Dr. Adolph Lombardi
- AAHKS Presidential Award
  - Dr. Frank Voss



# 2015 Fall Meeting Symposia

- Clinical Practice  
Difficult Cases
- Outcome  
Measures
- Metal Reactions
- Risk Stratification
- Outpatient  
Arthroplasty
- Bundled Payments
- FAI



# James A. Rand Award Paper

A Randomized Controlled Trial of  
Oral and IV Tranexamic Acid:  
The Same Efficacy at Lower Cost?

Yale A. Fillingham, MD  
Rush University





# A Randomized Controlled Trial of Oral and IV Tranexamic Acid: The Same Efficacy at Lower Cost?

Yale A Fillingham MD, Erdan Kayupov, MS, Darren Plummer, MD, Mario Moric, MS,  
Tad Gerlinger, MD, Craig J. Dalla Valle, MD

Double-blind, placebo-controlled, powered, RCT

1.95 g oral TXA vs 1g iv bolus TXA in TKA

Primary outcome: reduction in hemoglobin

## Results

Equivalent Hb reduction: 3.45 g/dL vs 3.31 g/dL (p<0.001)

Equivalent blood loss: 1267 mL vs 1229 mL (p<0.007)

Cost: \$14 vs \$47—108



# A Randomized Controlled Trial of Oral and IV Tranexamic Acid: The Same Efficacy at Lower Cost?

Yale A Fillingham MD, Erdan Kayupov, MS, Darren Plummer, MD, Mario Moric, MS,  
Tad Gerlinger, MD, Craig J. Dalla Valle, MD

## Impact

\$23 million to \$67 million annual savings

(700,000 TKA/year)



# Lawrence D. Dorr Award

Conversion Total Hip Arthroplasty:  
Is it a Primary or  
Revision Hip Arthroplasty?

Ran Schwarzkopf, MD, MSc  
NYU Langone



# Conversion Total Hip Arthroplasty: Is it a Primary or Revision Hip Arthroplasty?

Ran Schwarzkopf, MD and Mahta Baghoolizadeh, BS

ACS-NSQIP database dataset (75,000 procedures)

Conversion THA vs Revision THA vs Primary THA

Compared 53 pre- intra- and post-operative variables

## Results

17 variables different Conversion vs Primary ( $p < 0.0003$ )

1 variable different Revision vs Primary ( $p < 0.0003$ )

3 variables different Conversion vs Primary ( $p < 0.0003$ )



# Conversion Total Hip Arthroplasty: Is it a Primary or Revision Hip Arthroplasty?

Ran Schwarzkopf, MD and Mahta Baghoolizadeh, BS

## Impact

Conversion = Revision      Conversion  $\neq$  Primary

Wrong DRG

Ongoing Discussion with CMS, CJR Implications



# AAHKS Clinical Award

Liposomal Bupivacaine and Peri-articular Injection are Not Superior to Single Shot Intra-articular Injection for Pain Control In Total Knee Arthroplasty

Rajesh K. Jain, MD, MPH  
Reconstructive Orthopaedics  
Marlton, NJ



# Liposomal Bupivacaine and Peri-articular Injection are Not Superior to Single Shot Intra-articular Injection for Pain Control In Total Knee Arthroplasty

Rajesh K. Jain, MD, MPH, Scott D. Schoifet, MD, FACS, Manny D. Porat, MD, Gregory G. Klingenstein, MD, Jeremy J. Reid, MD, Robert E. Post, MD

Single-blind, prospective, powered, RCT, 207 TKA

Intra-articular bupivacaine/morphine

vs

Peri-articular bupivacaine/morphine

Vs

Liposomal bupivacaine (PA)

Primary outcome: VAS Pain & narcotic need (MME)



# Liposomal Bupivacaine and Peri-articular Injection are Not Superior to Single Shot Intra-articular Injection for Pain Control In Total Knee Arthroplasty

Rajesh K. Jain, MD, MPH, Scott D. Schoifet, MD, FACS, Manny D. Porat, MD, Gregory G. Klingenstein, MD, Jeremy J. Reid, MD, Robert E. Post, MD

Single-blind, prospective, powered, RCT, 207 TKA

Primary outcome: VAS Pain & narcotic need (MME)

## Results

	IA	PAI	Lipo
Mean VAS :	3.95	vs 3.97	vs 3.86 (p=0.94)
MME/day :	100.7	vs 100.1	vs 98.9 (p=0.97)





# Liposomal Bupivacaine and Peri-articular Injection are Not Superior to Single Shot Intra-articular Injection for Pain Control In Total Knee Arthroplasty

Rajesh K. Jain, MD, MPH, Scott D. Schoifet, MD, FACS, Manny D. Porat, MD, Gregory G. Klingenstein, MD, Jeremy J. Reid, MD, Robert E. Post, MD

## Impact

Cost savings: \$4.92 vs \$315

Also Paper #36, DBRCT Lipo vs PAI



# Scientific Sessions (9)

13 RCTs

22% Level 1 Studies

Focus: Clinically Relevant, Practice Changing



# Scientific Session Highlights

## Knee

#9: Fixed vs Mobile TKA 10 yr RCT  
No difference

#13: Kinematic vs Mechanical Alignment in TKA RCT  
No difference



# Scientific Session Highlights

## Hip

#21: RCT Formal PT vs Independent Ex after THA  
No Difference

#22: Michigan Arthroplasty Registry  
DA vs Post THA Same Dislocation Rates (0.4%)

#24/25: 13 year f/u XLPE, 28 vs 36 heads  
No difference in Wear Rates or Osteolysis



# Scientific Session Highlights

## Infection

#27: RCT Oral Abx after 2-stage PJI  
Reduces Reinfection Risk (5% vs 20%)

#31/32 Injections Prior to TJA Increase Infection Risk  
Risk increases with shorter gap

